Misc

Skystar Bio-Pharmaceutical Reports 27% Growth in Revenue From Continuing Operations in First Quarter Fiscal Year 2010

15 years ago15 years ago

Gross Margin of 53%; $0.15 Diluted Earnings Per Share; Fiscal 2010 Top Line Guidance Increased to $45.5 Million to $47.5 Million